B Joyce Davison1, Andrew Matthew2, Abbie M Gardner3. 1. College of Nursing, University of Saskatchewan, Saskatoon, SK; 2. Department of Surgery, University of Toronto, Toronto, ON; 3. Department of Surgery, University of Toronto, Toronto, ON; ; Department of Psychiatry, University of Toronto, Toronto, ON.
Abstract
INTRODUCTION: There is no conclusive evidence that the robotic-assisted laparoscopic radical prostatectomy (RARP) is superior to conventional open radical prostatectomy (ORP) when it comes to recovery of urinary and sexual function, and that the former surgical option results in less decision regret. METHODS: Patients scheduled for both surgical procedures were surveyed prior to surgery, and then again at 6 and 12 months following treatment using the sexual and urinary modules of the Expanded Prostate Cancer Index Composite (EPIC) measure. Decision regret was measured at 12 months. Propensity score regression adjustment was used to account for differences between treatment groups by summarizing all covariate information into a single probability and to simulate randomization. RESULTS: At 12 months, urinary summary scores approached baseline levels, while urinary bother scores had returned to baseline. Sexual summary and bother mean scores decreased by about half of what they were at baseline for both treatment groups at 6 and 12 months. No significant differences in the groups' sexual summary and bother domains were identified at either 6 or 12 months. Both groups' scores for decision regret were low. Moderate correlations (r(2) range -0.333 to -0.368) were between current levels of urinary and sexual function and decision regret at 12 months. CONCLUSION: The results of our study found no significant difference in health-related quality of life outcomes based on surgical procedure at 12 months. Moreover, patients in both groups reported low levels of decision regret at 12 months. Further multi-site prospective studies are required to address this study's limitations.
INTRODUCTION: There is no conclusive evidence that the robotic-assisted laparoscopic radical prostatectomy (RARP) is superior to conventional open radical prostatectomy (ORP) when it comes to recovery of urinary and sexual function, and that the former surgical option results in less decision regret. METHODS:Patients scheduled for both surgical procedures were surveyed prior to surgery, and then again at 6 and 12 months following treatment using the sexual and urinary modules of the Expanded Prostate Cancer Index Composite (EPIC) measure. Decision regret was measured at 12 months. Propensity score regression adjustment was used to account for differences between treatment groups by summarizing all covariate information into a single probability and to simulate randomization. RESULTS: At 12 months, urinary summary scores approached baseline levels, while urinary bother scores had returned to baseline. Sexual summary and bother mean scores decreased by about half of what they were at baseline for both treatment groups at 6 and 12 months. No significant differences in the groups' sexual summary and bother domains were identified at either 6 or 12 months. Both groups' scores for decision regret were low. Moderate correlations (r(2) range -0.333 to -0.368) were between current levels of urinary and sexual function and decision regret at 12 months. CONCLUSION: The results of our study found no significant difference in health-related quality of life outcomes based on surgical procedure at 12 months. Moreover, patients in both groups reported low levels of decision regret at 12 months. Further multi-site prospective studies are required to address this study's limitations.
Authors: Sergey A Shikanov; Michael K Eng; Andrew J Bernstein; Mark Katz; Gregory P Zagaja; Arieh L Shalhav; Kevin C Zorn Journal: J Urol Date: 2008-06-12 Impact factor: 7.450
Authors: Florian R Schroeck; Tracey L Krupski; Suzanne B Stewart; Lionel L Bañez; Leah Gerber; David M Albala; Judd W Moul Journal: J Urol Date: 2012-01-15 Impact factor: 7.450
Authors: Jack A Clark; Thomas S Inui; Rebecca A Silliman; Barbara G Bokhour; Steven H Krasnow; Richard A Robinson; Monica Spaulding; James A Talcott Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Florian R Schroeck; Tracey L Krupski; Leon Sun; David M Albala; Marva M Price; Thomas J Polascik; Cary N Robertson; Alok K Tewari; Judd W Moul Journal: Eur Urol Date: 2008-06-23 Impact factor: 20.096
Authors: Jamie C Brehaut; Annette M O'Connor; Timothy J Wood; Thomas F Hack; Laura Siminoff; Elisa Gordon; Deb Feldman-Stewart Journal: Med Decis Making Date: 2003 Jul-Aug Impact factor: 2.583
Authors: Richard M Hoffman; Mary Lo; Jack A Clark; Peter C Albertsen; Michael J Barry; Michael Goodman; David F Penson; Janet L Stanford; Antoinette M Stroup; Ann S Hamilton Journal: J Clin Oncol Date: 2017-05-11 Impact factor: 44.544
Authors: Daniela Wittmann; Marsha Carolan; Barbara Given; Ted A Skolarus; Heather Crossley; Lawrence An; Ganesh Palapattu; Patricia Clark; James E Montie Journal: J Sex Med Date: 2014-10-31 Impact factor: 3.802
Authors: Donald S Strassberg; Suzanne M Zavodni; Paul Gardner; Christopher Dechet; Robert A Stephenson; Kelsey K Sewell Journal: Curr Urol Date: 2017-11-30